The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Results of the IBIS II Trial

Charles L. Shapiro, MD
Published Online: 4:17 PM, Tue December 17, 2013
Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Clinical Pearls:
  • IBIS II is a prevention study in over 3,000 women who were randomized to anastrozole vs placebo
  • Anastrozole proved to be 50% effective in presenting breast cancer, primarily ER+ breast cancer, compared to the placebo
  • There was only a 10% difference in the grades of musculoskeletal arthralgias when comparing anastrozole to the placebo

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.